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 Abstract 
 
Aims: To determine the role of p75 neurotrophin receptor (p75NTR) and the therapeutic 
effect of the selective small molecule p75NTR modulator, LM11A-31, in spinal cord injury 
(SCI) induced lower urinary tract dysfunction (LTUD) using a mouse model. 
 
Methods: Adult female T8-T9 transected mice, were gavaged daily with LM11A-31 (100 
mg/kg) for up to 6 weeks, starting one day before or seven days following injury.  Mice 
were evaluated in vivo using urine spot analysis, cystometrograms (CMGs) and external 
urethral sphincter (EUS) electromyograms (EMGs); and in vitro using histology, 
immunohistochemistry and western blot. 
 
Results: Our studies confirm the expression of p75NTRs in mouse bladder and dorsal horn 
of the lumbar-sacral (L6-S1) spinal cord which significantly decreased following SCI.  
LM11A-31 prevented or ameliorated the detrusor sphincter dyssynergia (DSD) and 
detrusor overactivity (DO) in SCI mice, significantly improving bladder compliance.  
Furthermore, LM11A-31 treatment blocked the SCI-related urothelial damage and 
bladder wall remodeling. 
 
Conclusion: Drugs targeting p75NTRs can moderate DSD and DO in mice, may identify 
pathophysiological mechanisms and have therapeutic potential in SCI patients.  
 Introduction 
 
Detrusor Sphincter Dyssynergia. Storage and emptying of urine from the bladder are 
dependent on coordinated contraction/relaxation of the smooth and striated muscles in 
lower urinary tract organs mediated by neural circuitry in the brain and spinal cord1.  
During storage, detrusor smooth muscle is relaxed, while the smooth and striated 
muscles of external urethral sphincter (EUS) contract to maintain continence.  The 
converse happens during micturition, when the detrusor smooth muscle contracts and the 
EUS relaxes.  This voluntary control of micturition is lost following spinal cord injury (SCI) 
rostral to the lumbosacral spinal segments, and the bladder becomes areflexic.  Following 
recovery from spinal shock, reflex bladder activity re-emerges with the formation of a 
spinal micturition pathway, and ultimately the bladder becomes hyperreflexic2.  SCI also 
leads to detrusor sphincter dyssynergia (DSD) which describes the simultaneous 
contraction of the bladder and EUS.  DSD is commonly attributed to the interruption of 
descending inhibitory pathways from the pontine micturition center (PMC) to EUS 
motoneurons in Onuf’s nuclei within the sacral spinal cord.  Various therapies have been 
employed to reduce DSD; however, the results have failed to satisfy the Level 1 
recommendation3.  DSD causes urinary retention—a major problem in the care of SCI 
patients. The resultant high intravesical pressures can induce ureteral reflux and 
potentially lead to renal failure. 
Detrusor Overactivity (DO). Urinary retention, bladder distention and inflammation, 
secondary to DSD-induced outlet obstruction, lead to bladder wall hypertrophy and DO, 
where the latter has neurogenic and myogenic components. Neurogenic detrusor 
overactivity (NDO) results from neural remodeling and afferent sensitization, whereas 
 myogenic DO occurs due to a combination of increased coupling of putative pacemaker 
interstitial cells and detrusor smooth muscle and stretch-evoked urothelial ATP release4.  
Increased myogenic activity may also stimulate mechanosensitive afferents5 to trigger 
reflex bladder contractions and exacerbate NDO symptoms. 
Neurotrophic factors and p75NTRs.  Nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) are released by detrusor smooth muscle, mast cells and 
urothelial cells in various pathologies6.  Mature NGF and BDNF are enzymatically  
processed within secretory vesicles from their proneurotrophins (proNGF/proBDNF) 
before release7.  During pathology8, their overexpression exceeds the rate of processing 
leading to unregulated release of proneurotrophins which differ from mature forms in their 
affinity for p75NTRs, the expression of which is increased following SCI in the bladder and 
neuronal pathways governing micturition9.  Furthermore, proNGF/proBDNF preferentially 
activate the p75NTR-sortilin complex.  Sortilin is transport protein involved in the 
organization of intracellular cargo between membrane compartments, that when 
activated by proneurotrophins in conjunction with p75NTR can induce apoptosis in many 
cell types10.  The mature neurotrophins activate their cognate tropomyosin receptor 
kinase (Trk) and p75NTR heterodimer, promoting survival and differentiation (Figure 1A). 
Upon proneurotrophin binding, full-length p75NTRs undergo proteolytic cleavage, 
removing the extracellular domain (ECD) and leaving the membrane bound carboxyl-
terminal fragment.  Further cleavage generates the soluble intracellular domain (ICD), 
which can translocate to the nucleus11, activating apoptotic transcriptional targets in 
addition to pathways activated by the full-length p75NTR 10. 
 LM11A-31 and LM11A-24. These are small organic molecules identified as 
modulators of p75NTRs through in silico screening for potential to mimic the binding activity 
of the loop 1 domain of NGF and competitively antagonize proneurotrophin binding12.  
However, these molecules can also have the potential to directly activate p75NTR 
associated signaling13.  LM11A-31 partitions mostly to the CNS and has been shown to 
improve motor coordination after spinal cord contusion injury in mice14.  The absence of 
toxicity or exacerbation of injury-associated pain14 in previous studies using LM11A-31 
affirms its possible therapeutic potential for treating neurogenic LUTD.  Therefore, our 
aim was to determine the effect of oral administration of LM11A-31 on LUTD in a thoracic 
SCI mouse model. 
 
Methods 
 
SCI surgery (T8-T9 transection). SCI surgery was performed as previously 
described5.  Briefly, adult female C57BL/6 mice (18-25 g) were anesthetized with 
isoflurane (5% induction/1.5% maintenance) and a laminectomy performed at the T8-T9 
spinal level.  The cord was completely transected, the resultant space between the cut 
ends filled with hemostatic sponge to minimize bleeding and the muscle layer and 
overlying skin sutured.  Subsequently, bladders were expressed by gentle abdominal 
compression, twice-daily, for one week.  The animals were used for experiments one day 
to six weeks following SCI. 
LM11A-31 and LM11A-24 treatment. Both LM11A-31 and LM11A-24 were 
synthesized in house.  Mice were administered once-daily gavage of water (100 μl) in 
controls and aqueous solutions of LM11A-31 or LM11A-24 (100 mg/kg) in treated groups.  
 Treatment was initiated either a day before or seven days after SCI, until experimental 
endpoints.  Spinal cord intact mice were also administered the drugs or vehicle for a seven 
day period, a week following SCI. 
Histology. Mice were sacrificed according to the University’s Institutional Animal 
Care and Use Committee approved methods, urinary bladders dissected and opened 
longitudinally along the ventral aspect, flattened, fixed overnight in 10% 
paraformaldehyde, embedded in paraffin, sectioned transversely (3 μm) and stained with 
hematoxylin and eosin or 2% acidified toluidine blue (mast cell stain) for light microscopy. 
Enzyme linked immunosorbent assay (ELISA). Urine samples were collected from 
the bladders of mice immediately following euthanasia using a 32-gauge insulin syringe, 
and immediately frozen on dry ice and stored at -80ºC.  Levels of p75NTR ECD were 
evaluated using a mouse NGFR/p75ECD rapid ELISA kit (Biosensis) according to 
manufacturer instructions. 
Western blotting. The mucosa and detrusor muscle layers were separated by blunt 
dissection, and samples were homogenized (Lysing Matrix D using FastPrep-24, MP 
Biomedicals) in Hank’s balanced salt solution containing complete protease inhibitor 
cocktail (1 tablet/10 ml, Roche) and phosphatase inhibitor cocktail (Sigma, 1:100).  After 
centrifugation (10,000 x g; 15 min at 4ºC), the supernatant was collected, and the 
membrane protein fraction was prepared by suspending pellets in lysis buffer (0.3 M 
NaCl, 50 mM Tris-HCl pH7.6 and 0.5% Triton X-100) with protease/phosphatase 
inhibitors as above.  Supernatants were pooled for whole cell lysates and protein 
concentrations determined using a BCA protein assay (Pierce).  After denaturation 
(100ºC for 5 min) in Laemmli sample buffer, 40 µg of each lysate was separated on a 4-
 15% TGX Stain-Free SDS-PAGE gel (Bio-Rad). Proteins were transferred to PVDF 
membranes and incubated overnight at 4ºC with primary antibodies against the ICD of 
p75NTR, proNGF, proBDNF and β-actin (details of antibodies in supplemental figure 13) 
diluted in Tris-buffered saline with 0.1% Tween-20 (TBS-T) containing 5% (w/v) milk.  
Membranes were incubated with appropriate horseradish peroxidase conjugated 
secondary antibodies in 5% (w/v) Milk TBS-T, washed, and incubated in WesternBright 
Quantum (Advansta) for chemiluminescent imaging (ChemiDoc MP, Bio-Rad).  Optical 
density of each protein species was normalized to total protein levels using Image Lab 
software (Bio-Rad). 
Immunofluorescence. Whole bladders and spinal cord segments were isolated, 
embedded in optimal cutting temperature medium and frozen on dry ice (n=3 per group).  
The bladders were sectioned (10 μm) on a cryostat and immediately processed for 
immunofluorescent detection of p75NTRs, tyrosine hydroxylase (TH) and calcitonin gene 
related protein (CGRP) using a previously described protocol15. The p75NTR expression 
and p75NTR-CGRP/TH colocalization analysis were performed using ImageJ (NIH) and 
MATLAB (MathWorks Inc.) software, respectively. 
Urine spot assay. Mice were placed individually in clean metabolic cages lined with 
Whatman filter paper at the bottom for two hours, between 11 a.m. and 2 p.m., with water 
and food withheld for the duration of the assay.  The filter papers were visualized under 
UV light, images retained as TIFF files and analyzed using ImageJ software using a 
previously described method16 (see supplemental figure 8). 
Transepithelial resistance (TER) measurements. Following euthanasia, bladders 
were excised, washed with oxygenated Ringer’s solution, opened to form a sheet, 
 mounted on a nylon ring (0.09 cm2 exposed area) and placed in Ussing chambers under 
constant oxygenation and temperature control.  TER was determined by passing current 
through Ag/AgCl electrodes and measuring the voltage deflection (Vt) with another pair 
of electrodes.  Data were digitized for display, analysis and storage. 
Decerebrate CMG and EMG recordings. Mice were anesthetized using isoflurane 
and an incision made in the neck to expose the carotid arteries and trachea.  Ligatures 
were placed around the carotids to decrease cerebral blood flow and a tracheotomy 
performed using PE-60 tubing.  After a craniotomy, the brain rostral to the supracollicular 
level was sectioned.  Decerebration allowed cystometric assessment to be performed 
without anesthetics which can block reflex bladder contractions.  A PE-50 catheter was 
inserted through the bladder dome, secured using a suture and connected to a pressure 
transducer and syringe pump.  Two stainless steel 50 μm electrodes were inserted 
transperineally 1 mm lateral to the urethra to record EUS activity.  The bladder was 
emptied manually and then filled with saline at 0.01 ml/min until reflex contractions were 
elicited to perform voiding cystometry. 
Statistical Analysis. Quantitative data are shown as mean ± SD.  One and two-way 
ANOVA was used to determine between group differences with Tukey’s multiple 
comparisons test, differences between data sets were tested with unpaired Student’s t-
test, and skewed data sets with a Mann-Whitney U test; significance was p<0.05. 
Study Approval. All animal procedures were compliant with the National Institutes 
of Health “Guide for the Care and Use of Laboratory Animal” and received institutional 
ethical approval. 
 
 Results 
LM11A-31 improves voiding efficiency. In vivo voiding patterns were assessed 
using urine spot test analysis over a two-hour period (Figure 2 and Supplemental Figure 
7).  Spinal cord intact mice were continent and voided in one area of the cage (Figure 
2A).  Voiding patterns and voided volumes of spinal cord intact mice were not affected by 
daily administration of LM11A-24 (Figure 2B) or LM11A-31 (Figure 2C), the maximal 
dosage shown to improve motor recovery following spinal cord contusion injury14.  Two 
weeks post-SCI, mice exhibited random urine spots and a significant decline in voided 
volumes (Figure 2D).  Daily treatment with the peripherally acting LM11A-2417 did not 
affect these parameters (Figure 2E), but the centrally acting LM11A-31 significantly 
increased the voided volumes (p<0.05 compared to vehicle treated SCI mice, Student’s 
t-test), indicating improvement in voiding efficiency (Figure 2F).  A table listing the spot 
test voided volumes and calibration data are shown in Supplemental Figures 7 and 8. 
LM11A-31 ameliorates DSD and NDO. The effects of targeting p75NTR inhibition 
on bladder and EUS function were assessed by decerebrate CMG and EUS-EMG 
measurements.  Spinal cord intact mice showed long intercontractile intervals and low 
filling pressures (Figure 3A) along with EUS bursting and reduction of tonic sphincter 
activity during voiding (Figure 3A-1).  At two weeks post-SCI, there was a loss of regular 
micturition patterns, emergence of nonvoiding contractions (i.e. DO) and increased EUS 
tonic activity with decreased bursting in response to bladder contractions, i.e., DSD 
(Figures 3B, B-1).  Daily treatment with LM11A-31 initiated one week following SCI 
reduced nonvoiding bladder contractions, decreased concurrent EUS tonic activity and 
increased bursting to improve voiding efficiency (Figures 3C, C-1).  The amelioration of 
 DO and DSD was accompanied by a significant increase in bladder compliance.  Daily 
LM11A-31 prevented the development of NDO in the experimental assessments at the 
six week timepoint (Figures 3D-F).  Data tables for CMG and EMG recordings are shown 
in supplemental figures 9 and 10. 
LM11A-31 preserves urothelial structure and barrier function. SCI resulted in acute 
disruption of the urothelium (Figures 4B vs. A). When mice were administered LM11A-31 
starting one day pre-surgery, bladders showed protection against SCI-induced urothelial 
loss (Figure 4C).  At 10 days post-SCI, further morphological changes to the bladder were 
manifested as hyperplasia of the urothelium and lamina propria as well as detrusor 
hypertrophy (Figure 4D).  These changes were prevented by daily LM11A-31 treatment 
(Figure 4E).  The loss of barrier function in SCI animals was apparent from a significant 
reduction of transepithelial resistance (TER) and this adverse event was prevented by 
administration of either LM11A-24 or LM11A-31 initiated prior to SCI (Figure 4F).  
Toluidine blue staining demonstrated that the numbers of activated mast cells in SCT 
bladders two weeks following injury were significantly greater than in control uninjured 
bladders (8.1 ± 1.6 cells/mm2 versus 1.4 ± 1.6 cells/mm2, respectively, p < 0.01, unpaired 
Student’s t-test).  Daily treatment with LM11A-31 initiated one day before SCI significantly 
decreased the mast cell numbers (3.2 ± 1.7 cells/mm2, p < 0.01 versus untreated SCI). 
LM11A-24 treatment also decreased the number of activated mast cells, but less 
significantly (6.5 ± 2.2 cells/mm2, p = 0.05 versus untreated SCI). 
Alteration in p75NTR and proneurotrophin levels in the urine and urinary bladder 
following SCI. Urine levels of p75NTR ECD were evaluated by ELISA, one to seven days 
following SCI (Figure 4G).  A sharp rise in p75NTR ECD levels noted one day post-injury, 
 was decreased by LM11A-31 pretreatment, SCI-induced elevations of the p75NTR ECD 
were observed at much lower levels for up to seven days post-injury. 
Western blot analysis showed full-length p75NTRs are more highly expressed in the 
detrusor than the mucosa and these levels are decreased at seven days post SCI.  
LM11A-31 treatment blocked the loss of p75NTR expression in SCI animals (Figure 4H 
and I).   LM11A-31 treated mice had elevated proBDNF levels compared to untreated SCI 
and control mice.  The protein level of proNGF was not significantly different in the 
mucosa or detrusor samples from control, SCI and SCI + LM11A-31 groups (data not 
shown).  The p75NTR and proBDNF levels normalized to β-actin are summarized in the 
bar graphs in Figure 4I. 
Expression of p75NTRs on TH- and CGRP-positive nerve fibers in bladder and 
spinal cord segments. In spinal cord intact mice, p75NTRs were found throughout the 
bladder wall and colocalized with TH- (6.1 ± 3.7% of p75NTR labeling in bladder wall) and 
CGRP-positive (8.3 ± 1.8% of p75NTR labeling in bladder wall) nerve fibers (Figures. 5A, 
D, J, K and L).  There was no detectable p75NTR labeling on cholinergic nerves or 
fibroblasts (not shown).  At seven days post-SCI, p75NTR expression decreased in the 
detrusor layer (6.9 ± 1.9% of detrusor area in controls versus 3.7 ± 1.8% in SCI) while 
maintaining a similar degree of colocalization with TH- or CGRP-positive nerves; 3.1 ± 
1.8% and 6.4 ± 1.8% colocalization with p75NTR, respectively. (Figures 5B, E, J and K) 
There was also increased expression in basal/intermediate urothelial cells which was not 
observed in spinal cord intact mouse bladders (Figure 5L and M). Daily LM11A-31 
treatment of SCI mice did not significantly alter total p75NTR expression in the urothelium 
or detrusor, nor the colocalization of p75NTR with CGRP or TH compared to untreated SCI 
 mice (Figure 5J and K).  The % area of p75NTR expression in the urothelium did not differ 
between spinal cord intact (1.2 ± 0.6 %), SCI (2.3 ± 2.3%) and SCI mice with LM11A-31 
(1.4 ± 1.3%) or LM11A-24 (2.2 ± 0.8%) treatment.  In control mice, expression of p75NTR 
in L6-S1 spinal cord segment was limited to the dorsal horn (45.0 ± 11.0% of dorsal horn 
area) with the highest density in the lamina-II region (Figure 5G).  At seven days post-
SCI, there was a significant decrease in p75NTR expression in the lamina-II region of the 
dorsal horn (from 77.8 ± 16.8% in controls to 44 ± 19.6% of lamina-II area) (Figure 5H), 
which was not altered by LM11A-31 treatment (42.0 ± 3.7%) (Figure 5I). 
 
Discussion 
SCI-induced LUTD is described by the symptoms and signs including DSD, NDO, 
myogenic DO, and urothelial barrier disruption, hypertrophy and hyperplasia.  These 
physiological and histological changes correlate with increased production of 
proNGF/proBDNF by denervated tissues within the spinal cord and bladder wall following 
SCI18. 
The expression of p75NTRs is previously reported to be localized in urothelium of 
rat bladders19 and in SCI patient biopsies9, where p75NTRs likely contribute to the urothelial 
injury in SCI.  Our study suggests that under normal conditions, there is robust expression 
of p75NTRs in the urinary bladder where a select population colocalize with CGRP and TH-
positive innervating the mouse urothelium and detrusor (Figures 5A, D and K) some of 
which could potentially originate from bladder innervating neurons in L1 and S1 dorsal 
root ganglia (supplemental figure 11). LM11A-31 treatment did not affect the decrease in 
p75NTR or the % colocalization with TH or CGRP, suggesting this drug may be altering 
 functional properties of bladder nerves to bring about their therapeutic effect.  SCI have 
been shown to enhance bladder sensory neuron firing due to increased Na+ channel 
currents density and a similar effect has been demonstrated with chronic intrathecal NGF 
administration2.  The effect of LM11A-31 on bladder afferent firing has yet to be 
determined, however, our data show that treatment can ameliorate SCI-induced DO and 
significantly improve bladder compliance, suggesting an effect on afferent activity.  
Following SCI, there is increased p75NTR expression in the basal/intermediate urothelium 
(Figure 5M) which could correlate with proliferating cells found during the first seven days 
after SCI20. This suggests neurotrophin signaling may be involved in maintaining 
urothelial differentiation or regeneration of the urothelium following injury.  Strong p75NTR 
expression is also noted in the dorsal horn of L6-S1 spinal cord segments (Figure 5G), as 
reported previously21.  The high level of p75NTR in the detrusor layer noted in western 
blots (Figure 4H-I) could be due to higher density of p75NTR positive nerve fibers compared 
to the mucosa (Figure 5).  Studies with urothelial NGF overexpressing mice22 also showed 
enhanced expression of p75NTR in the detrusor layer compared to control mouse 
bladders.  Our data demonstrate that p75NTR ECD fragments are elevated in acute SCI 
(Figure 4G), suggesting that binding of proneurotrophins is inducing the p75NTR cleavage.  
However, we cannot rule out that some of the ECD protein excreted in the urine may be 
contributed by other organs/tissues.  Pretreatment with LM11A-31 blocked the rise of 
urinary p75NTR ECD levels that occurs within 24 hours of SCI, suggesting LM11A-31 
treatment in the clinical setting may be most beneficial within hours following SCI to 
prevent the activation of neurodegenerative pathways.  Nonetheless, we have also 
demonstrated that LM11A-31 ameliorated DSD and DO when given one week following 
 SCI (Figure 3C).  Our data showed a significant decline in measurable amounts of 
proBDNF by seven days post-SCI and this decline was not observed in LM11A-31 treated 
groups (Figure 4I) suggesting displacement of proBDNF by LM11A-31 raises the levels 
of free proBDNF.  This trend was not observed with proNGF, whose production in bladder 
was lower than proBDNF (not shown).  There may be multiple factors (e.g. inflammation 
induced mRNA instability, disruption in protein translation mechanisms) that could be 
attributed to decreased proneurotrophin levels in SCI.  Enhanced uptake and retrograde 
transport of neurotrophins from the bladder, proposed for changes in NGF levels following 
SCI23, could potentially be involved.  As LM11A-31 treatment prevented the decline in 
proBDNF, it suggests the drug is preventing proneurotrophin binding and subsequent 
transport, supporting the concept of SCI-induced alterations in neurotrophin uptake. 
We propose that unregulated release of proNGF/proBDNF from vesicular stores24 
stimulates p75NTR-positive nerves and the urothelium to initiate degenerative pathways. 
The consequent urothelial disruption, urine infiltration and inflammation lead to increased 
release of excitatory transmitters25 from sensory nerves that further potentiates the 
inflammatory processes to promote afferent sensitization and exacerbation of NDO.  The 
urothelium shows constitutive expression of NGF which is believed to participate in 
maintaining normal bladder function25.  During the acute phase of SCI, it could be 
speculated that urothelial disruption and nerve injury causes a rapid increase in 
neurotrophin expression23.  Our data suggest proneurotrophin signaling predominates 
within 24 hours following SCI and may be responsible for the detrimental p75NTR signaling 
in the bladder.  At later time points following SCI, there may be proportionally more mature 
neurotrophins in the bladder than under normal conditions23 as a compensatory 
 mechanism to promote nerve growth.  Loss of bladder and L6-S1 p75NTR expression in 
SCI suggests impairment of afferent and efferent function in the bladder precedes the 
urinary retention noted acutely following injury.  Loss of nerve fibers is also noted in 
bladders of SCI patients26.  Activation of p75NTR leads to receptor internalization and 
retrograde axonal transport to induce transcriptional changes27 and may account for 
decreased p75NTR expression in the bladder following SCI.  LM11A-31 treatment did not 
change bladder or L6-S1 spinal cord p75NTR expression compared to vehicle treated SCI 
mice (supplemental figure 12), suggesting it may rather augment sensory nerve activity 
in the dorsal root ganglia or L3-L4 EUS centers to ameliorate SCI-induced DO and DSD. 
The actions of LM11A-31 and LM11A-24 were compared to elucidate the sites of 
action responsible for the observed effects, because LM11A-31 crosses the blood-brain 
barrier14 and may act on the CNS and periphery, whilst LM11A-24 has mainly peripheral 
actions14,17.  Both agents did not alter voiding patterns when given to animals with intact 
spinal cords (Figures 2B, C).  In SCI animals, LM11A-31, but not LM11A-24, was able to 
ameliorate NDO and DSD and increase voided volumes (Figure 2F and E, respectively 
and Supplemental Figure 7).  However, both LM11A-24 and LM11A-31 could prevent 
urothelial barrier disruption (Figure 4F), demonstrating a shared peripheral site of action 
for both ligands.  Preventing urothelial disruption may account for the decreased number 
of activated mast cells in the bladder wall, however, mast cells also express p75NTR and 
we cannot exclude a direct effect of p75NTR modulators on these cells.  We infer that 
central actions of LM11A-31 are critical for the improvement of DSD and NDO and 
peripheral actions of the drug may further augment the central effects. 
 Based on our findings, a description of our hypothesis for the development of SCI-
induced DSD and NDO and putative therapeutic sites of action of LM11A-31/24 are 
shown in supplemental figure 6. 
 
Conclusion 
 The proposed therapeutic use of LM11A-31 to treat SCI-induced LUTD is clinically 
relevant as there are currently no pharmacological agents to treat DSD.  This agent also 
has therapeutic effect on NDO, can be administered orally and is safe and has entered 
phase II clinical trials for Alzheimer’s disease28.  
 Figure legends 
Figure 1. Schematics of p75NTR signaling pathways A) The p75NTR signals through 
dimerization with sortilin or Trk receptors.  p75NTR-sortilin complexes will preferentially 
bind proNGF/proBDNF that activate apoptotic signaling cascades.  Conversely, p75NTR-
Trk receptors bind to mature neurotrophins to activate cell survival pathways.  LM11A-31 
is a dual-action drug that can downregulate apoptotic JNK signaling though the p75NTR-
sortlin dimer, while promoting activation of AKT-mediated survival pathways through 
disinhibition and/or activation of the TrkA/BNTR-p75 dimer in UROtsa cells challenged with 
protease resistant proNGF. 
 
Figure 2. Urine spot analysis and the beneficial effect of LM11A-31 in SCI mice. 
Tests were conducted on control or SCI mice, receiving vehicle (water) or LM compound 
(n≥4).  A) Normal voiding pattern from a mouse with an intact spinal cord receiving water.  
B) A control mouse receiving LM11A-24 (100 mg/kg/day).  C) A control mouse receiving 
LM11A-31 (100 mg/kg/day).  D) Voiding pattern of a SCI mouse receiving water.  E) SCI 
mouse receiving LM11A-24.  F) SCI mouse receiving LM11A-31. 
 
Figure 3. LM11A-31 ameliorates SCI-induced DSD and NDO. A) Control mouse.  
The inset (A1, right) shows the boxed area of the expanded time-base.  B) SCI mouse 
two weeks post-injury, receiving vehicle (water).  C) SCI mouse receiving LM11A-31 
starting one week post-SCI (n≥4).  D) SCI mouse receiving LM11A-24 starting one week 
post-SCI.  E) Control mouse, CMG recording.  F) SCI mouse six weeks post-injury, 
 receiving vehicle (water).  G) SCI mouse six weeks post-injury, receiving LM11A-31 
starting from the day prior to injury. 
 
Figure 4. Pretreatment with LM11A-31 or -24 prevents SCI-induced adverse 
morphological changes in the bladder wall. A) H&E stained section of a control mouse 
bladder.  B) Bladder section of a SCI mouse (one day post-injury) receiving water.  C) 
Bladder section of a SCI mouse (one day post-injury) administered LM11A-31.  D) 
Bladder section of a SCI mouse (10 days post-injury) receiving water.  E) Bladder section 
of a SCI mouse bladder (10 days post-injury) receiving LM11A-31. (A. – E., n≥3).  F) 
Value of TER in bladder wall sheets from control and SCI mice (one day post-injury) with 
or without LM11A-31 or LM11A-24 treatment.  All treatments commenced one day prior 
to injury.  Mean data ± SD; p<0.05 vs. control (n≥4, unpaired Student’s t-test).  G) p75NTR 
ECD levels measured by ELISA (Biosensis) from mouse urine.  These values dramatically 
increased one day following SCI (*, p<0.05, n=4) in comparison to control animals (n=6).  
At this time point, pretreatment with LM11A-31 significantly decreased the amount of 
cleaved p75NTR ECD (**, p<0.05, n=4).  The p75NTR ECD levels measured three days 
post-transection, were comparatively lower, and the levels were sustained until seven 
days post-injury.  The LM11A-31 treatment decreased the sustained p75NTR ECD levels 
in the urine at three and seven days following SCI.  H) Western blot analysis of p75NTRs, 
proBDNF and β-actin in the mucosa and detrusor of control, SCI and LM11A-31 treated 
mice seven days post-injury.  The full-length p75NTR protein (75 kDa band) was highest 
in control samples and significantly decreased in both mucosa and detrusor layers 
following SCI.  Daily treatment with LM11A-31 prevented the decrease in full-length 
 p75NTR.  The antibody used for p75NTR detection also detected multiple smaller weight 
bands resulting from proteolytic cleavage following receptor activation.  I) Relative 
expression of p75NTR and proBDNF normalized to β-actin. * p<0.05, versus control 
samples. 
Figure 5. Immunofluorescent labelling of p75NTRs, their colocalization with 
Calcitonin Gene-Related Peptide (CGRP) and Tyrosine Hydroxylase (TH)-positive nerves 
– effect of LM11A-31.  A) p75NTRs (green) were expressed on TH-positive structures (red) 
in spinal cord (SC) intact mouse bladders.  B) Seven days post-SCI.  C) p75NTRs and their 
colocalization with TH-positive nerves was present in bladders of SCI mice (seven days 
post-injury) pretreated with LM11A-31.  The colocalization between SC intact, SCI and 
SCI with LM11A-31 treatment were not significantly different; p>0.05, One-way ANOVA 
with Tukey’s multiple comparison test.  D) p75NTRs also colocalized with bladder CGRP-
positive nerves (red) in SC intact animals.  Colocalization is indicated by merged yellow 
fluorescence and highlighted with yellow arrows.  E) Seven days post-SCI: p75NTR-
immunoreactivity (green) decreased compared to SC intact mice, the % area colocalized 
with CGRP (red) did not significantly change.  F) Expression level of p75NTR and 
colocalization of p75NTRs with CGRP-positive nerves was not found to differ from vehicle 
treated SCI mice (DT = detrusor; LP = lamina propria; and UT = urothelium).  G) p75NTR 
expression localized to the dorsal horn (white outlined region) of L6-S1 spinal cord 
segments in SC intact mice.  H) p75NTR labeling in seven day post-SCI mouse with 
decreased expression in lamina-II region. I) SCI mice with LM11A-31 for seven days. J) 
Colocalization analysis of p75NTR CGRP and K) TH immunofluorescence.  The % area 
that overlapped between p75NTR and CGRP or p75NTR and TH immunofluorescence were 
 quantified using MATLAB software within the total bladder wall area as defined by DAPI 
staining.  L) p75NTR and CGRP expressing fiber in SC intact mouse urothelium (white 
bordered region).  M) p75NTR expression in urothelial basal layer of SCI mouse bladders 
which was not found in SC intact mice. Similar urothelial staining profile was also seen 
with SCI + LM11A-31 and SCI + LM111A-24 treated mice.  Graphical representation of 
% area expression of p75NTR in the bladder wall and L6-S1 dorsal horn are shown in 
supplemental figure 12. 
 
Supplemental figure 6.  Mechanisms of proneurotrophins in SCI-induced LUTD 
and amelioration by LM11A-31 and -24.  A) The p75NTR signals through dimerization with 
sortilin or Trk receptors.  p75NTR-sortilin complexes will preferentially bind 
proNGF/proBDNF that activate apoptotic signaling cascades.  Conversely, p75NTR-Trk 
receptors bind to mature neurotrophins to activate cell survival pathways.  Table 1) 
Neurotrophin receptors and their ligands.  B-C) Schematic of neural connections that 
regulate voiding and the alterations following SCI that contribute to DSD and bladder 
dysfunction).  B) Under normal conditions, the urinary bladder and EUS receive 
parasympathetic inputs from the L6-S1 spinal cord via pelvic and pudendal nerves, 
respectively.  These inputs are regulated by supraspinal sites to coordinate afferent input 
[1] to the PMC that results in outflow to parasympathetic neurons [2] for bladder 
contraction and activation of inhibitory neurons [3] that act on motoneurons in Onuf’s 
nuclei to relax the EUS.  In rodents, there are also inhibitory interneurons in the L3-L4 
region that project to Onuf’s nuclei to promote EUS bursting [4] and death of these 
inhibitory interneurons may contribute to the development of DSD.  C) Data in Figure 5G-
 I demonstrate the selective expression of p75NTRs in the dorsal horn of a mouse L6 spinal 
cord segment whose selective stimulation by LM11A-31 leads to the remodelling that we 
hypothesize includes afferent projections to parasympathetic efferent nerves [5] that 
accounts for the bladder to spinal cord reflex.  We propose that the action of LM11A-31 
on cell pro survival signaling pathways allows it to promote growth of afferent projections 
to the L3-L4 region [7] and preserve the survival of inhibitory neurons in the L3-L4 region 
to alleviate DSD.  [8] LM11A-31 prevents proneurotrophin binding to p75NTRs on 
sympathetic and sensory nerve endings in the bladder wall, to prevent urothelial 
disruption and afferent sensitization and the development of NDO, respectively. 
 
Supplemental Figure 7.  Voided volumes calculated from spot tests using ImageJ. 
 
Supplemental Figure 8.  Calibration data for spot test analysis. 
 
Supplemental Figure 9.  Values of pressure threshold (PT), maximal voiding 
pressure (MVP), baseline pressure (BP), intercontraction intervals (ICI), bladder 
compliance (BC), the number of nonvoiding contractions (NVC), voided volumes (VV) and 
residual volumes (RV) from cystometric recordings represented in figure 3 (n≥4).  
(*p<0.05 compared to control group, unpaired Student’s t-test). 
 
Supplemental Figure 10.  Values of contraction duration (CD), voiding duration 
(VD) and EUS bursting activity in control, 2 weeks SCI and 2 weeks SCI with LM11A-31 
 therapy started a week following injury (n≥4).  (*p<0.01 compared to both control and 2 
weeks SCI with LM11A-31 therapy, unpaired Student’s t-test). 
 
Supplemental Figure 11.  Coexpression of p75NTR and TH or CGRP in DRG 
neurons innervating the mouse urinary bladder. Bladders of SC intact mice were injected 
with 10 µl of 2% fast blue solution and L1 and S1 DRG were isolated after one week and 
examined for expression of p75NTR and TH or CGRP on bladder specific sensory neurons 
by immunofluorescence.  A) p75NTR and TH were found to colocalize on neurons in L1 
DRG which send projections to the bladder through the hypogastric nerve (white arrows).  
B) S1 DRG (that send projections via pelvic nerve) also showed a small number of fast 
blue labeled sensory neurons that colocalized with p75NTR and TH (white arrow).  These 
indicate that some p75NTR + TH-positive fibers in the bladder could be from sensory 
neurons.  In C) L1 DRG and D) S1 DRG, p75NTR and CGRP were found to colocalize on 
fast blue labeled neurons (white arrows). 
 
Supplemental Figure 12.  Quantification of p75NTR expression in the urothelial and 
detrusor layers and L6-S1 spinal cord segment.  The percentage area of p75NTR 
immunofluorescence was quantified using ImageJ software in urothelial, detrusor and 
dorsal horn region.  Labeling in the urothelial layer was not significantly altered in control, 
SCI, and treatment groups.  p75NTR levels significantly decreased in the detrusor layer 
following SCI (*p<0.05 compared to SC intact, Two-way ANOVA with Tukey’s multiple 
comparisons test).  LM11A-31 or LM11A-24 treatment in SCI mice did not alter detrusor 
layer p75NTR expression compared to vehicle treated SCI mice.  The L6-S1 spinal cord 
 p75NTR expression was decreased in lamina-II region (**p<0.001 compared to SC intact, 
Two-way ANOVA with Tukey’s multiple comparisons test) and did not change with 
LM11A-31 treatment. 
 
Supplemental figure 13.  Table of antibodies used for immunofluorescence and 
western blots.  
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Spot Test
Data
SC
intact
SCI
2 wks p
water 200±24 102±55 < 0.05
LM11A-24 241±70 109±40 < 0.05
LM11A-31 223±42 263±97*
Total volume, μl
* - p < 0.05 compared to SCI with water 
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CMG Parameters PT, cmH2O
MVP,  
cmH2O
BP, 
cmH2O
ICI, sec BC,  μl/cmH2O
NVC/10
min VV, μl RV, μl
control 8 ± 4 40 ± 10 4 ± 3 412 ± 24 15 ± 4 0 60 ± 8 9 ± 7
SCI, 2 wks 14 ± 6 24 ± 5 9 ± 5 197 ± 18* 7 ± 3* 6 ± 2* 30 ± 9* 400 ± 9*
SCI, 2 wks + 
LM11A-24 17 ± 1 32 ± 1 13 ± 2 211 ± 56* 9 ± 3 6 ± 2* 35 ± 8* 388 ± 18*
SCI, 2 wks + 
LM11A-31 7 ± 1 36 ± 2 4 ± 1 396 ± 37 22 ± 4 0.2 ± 0.4 64 ± 5 28 ± 8*
SCI, 6 wks 12 ± 8 52 ± 1 11 ± 2 43 ± 13* 7 ± 2* 13 ± 3* 186 ± 6* 550 ± 5*
SCI, 6 wks + 
LM11A-31 8 ± 2 49 ± 9 6 ± 2 510 ± 144 47 ± 10* 4 ± 2 85 ± 24 99 ± 8*
Supplemental 
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EMG Parameters contraction duration, sec
voiding 
duration, sec burst number burst/sec
control 18.5 ± 1.6 5.3 ± 1 18 ± 4 3.3 ± 0.3
SCI, 2 wks 50.2 ± 3.7* 11.3 ± 4.7* 8 ± 4* 0.7 ± 0.2*
SCI, 2 wks + LM11A-31 16 ± 2 4 ± 0.7 15 ± 3 3.8 ± 0.9
SCI, 2 wks + LM11A-24 51.6 ± 3.5** 13.5 ± 3.2** 7.8 ± 0.8** 0.6 ± 0.1**
(*, ** -- p < 0.01 compared to both control and 2 weeks SCI with LM11A-31 therapy
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Primary Antibodies (WB: western blot, IF: immunofluorescence)
Antibody Host Concentration Company Catalogue number
p75NTR intracellular 
domain Rabbit WB: 1:1000 Promega G3231
p75NTR extracellular 
domain Goat IF: 1:1000 Neuromics GT15057
proNGF Rabbit WB: 1:1000 Life Technologies OSN00007G
proBDNF Mouse WB: 1:500 Santa Cruz sc-65514
β-actin Rabbit WB: 1:2000 Life Technologies PA-183
Tyrosine hydroxylase Rabbit IF: 1:500 Abcam ab112
CGRP Rabbit IF: 1:1000 Sigma C8198
CGRP Rabbit IF: 1:2000 Immunostar 24112
Secondary Antibodies (WB: western blot, IF: immunofluorescence)
Antibody Host Concentration Company Catalogue number
Anti-goat 
Alexafluor 488 Donkey IF: 1:500
Life 
Technologies A11055
Anti-rabbit Alexafluor 598 Donkey IF: 1:500 Life Technologies A21207
Anti-rabbit horseradish 
peroxidase (HRP) 
conjugate IgG
Donkey WB: 1: 2000 GE Healthcare NA934V
Anti-mouse HRP 
conjugate IgM Mouse WB: 1:2000 Santa Cruz sc-2318
Anti-goat HRP conjugate 
IgG Donkey WB: 1: 2000 Novex A16005
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